|
See related VFEND information |
|
|
|
Manufacturer |
Pfizer |
|
Distributor |
Hong Kong: Zuellig |
|
Contents |
Voriconazole |
|
Indications |
Treatment of invasive aspergillosis, candidemia in non-neutropenic patients, fluconazole-resistant serious invasive Candida infections (including C. krusei), esophageal candidiasis, serious fungal infections caused by Scedosporium spp & Fusarium spp in patients w/ progressive, possibly life-threatening infections.
Click to view VFEND detailed prescribing infomation |
|
Dosage |
Tab Loading dose Adult & Adolescent 12-16 yr ≥40 kg 400 mg 12 hrly for the 1st 24 hr. <40 kg 200 mg 12 hrly for the 1st 24 hr. Maintenance dose Adult & adolescent 12-16 yr ≥40 kg 200 mg 12 hrly. <40 kg 100 mg 12 hrly. Childn 2 to <12yr 200 mg bd. Esophageal candidiasis Maintenance dose Adult ≥40 kg 200 mg 12 hrly for a min of 14 days & at least 7 days following resolution. <40 kg 100 mg 12 hrly for a min of 14 days & at least 7 days following resolution. Vial IV infusion only. Max rate: 3 mg/kg/hr over 1-2 hr. Adult & Adolescent 12-16 yr Loading dose 6 mg/kg 12 hrly for the 1st 24 hr. Maintenance dose 4 mg/kg 12 hrly. Childn 2 to <12yr Maintenance dose 7 mg/kg bd.
Click to view VFEND detailed prescribing infomation |
|
Overdosage |
View VFEND overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Take at least 1 hr before or 1 hr after meals.). |
|
Contraindications |
Co-administration w/ terfenadine, astemizole, cisapride, pimozide, quinidine, sirolimus, rifampicin, carbamazepine, long-acting barbiturates (eg phenobarb), ritonavir, ergot alkaloids (eg ergotamine & dihydroergotamine), St. John's wort.
Click to view VFEND detailed prescribing infomation |
|
Special Precautions |
Hypersensitivity to azoles. Patients w/ potentially proarrhythmic conditions eg congenital or acquired QT-prolongation, cardiomyopathy, sinus bradycardia, existing symptomatic arrhythmias & concomitant medication known to prolong QT interval. Monitor & correct electrolyte disturbances (eg hypokalemia, hypomagnesemia & hypocalcemia) prior to initiation & during therapy. Monitor hepatic, renal & pancreatic function. Discontinue if exfoliative cutaneous reaction & skin lesion consistent w/ squamous cell carcinoma or melanoma occurs. Avoid sun exposure. Concomitant w/ methadone, short-acting opiates, oxycodone, phenytoin, rifabutin, ritonavir & efavirenz. May impair ability to drive or operate machinery. Women of childbearing potential should use effective contraception during treatment. Pregnancy & lactation. Childn <2 yr.
Click to view VFEND detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, visual disturbances, nausea, vomiting, diarrhea, abdominal pain, rash, fever, peripheral edema.
View ADR Monitoring Form |
|
Drug Interactions |
Terfenadine, astemizole, cisapride, pimozide, quinidine, sirolimus, rifampicin, carbamazepine, phenobarbital, ritonavir, ergot alkaloids (eg ergotamine & dihydroergotamine), St. John's wort, cyclosporin, tacrolimus, methadone, short-acting opiates, fentanyl, oxycodone, warfarin, coumarin anticoagulants, sulfonylureas, statins, benzodiazepines, vinca alkaloids (eg vincristine & vinblastine), NSAIDs, efavirenz, phenytoin, rifabutin, omeprazole, OCs, HIV-protease inhibitors, NNRTIs.
View more drug interactions with VFEND |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View VFEND storage conditions for details to ensure optimal shelf-life. |
|
Description |
View VFEND description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View VFEND mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
